CRISPR Therapeutics AG

NASDAQ:CRSP   3:59:56 PM EDT
119.92
+2.49 (+2.12%)
4:44:44 PM EDT: $119.40 -0.52 (-0.43%)
Products, Strategic Combinations

CRISPR Therapeutics & Capsida Biotherapeutics Announce Collaboration To Develop Gene-Edited Therapies For ALS And Friedreich’S Ataxia

Published: 06/15/2021 13:16 GMT
CRISPR Therapeutics AG (CRSP) - Crispr Therapeutics - Co & Capsida Biotherapeutics Announce Collaboration to Develop Gene-edited Therapies for Als and Friedreich’s Ataxia.
Crispr Therapeutics - Will Lead Research & Development of Friedreich’s Ataxia Program & Perform Gene-editing Activities for Both Programs.
Crispr Therapeutics - Capsida Will Lead Research and Development of Als Program and Conduct Capsid Engineering for Both Programs.
Crispr Therapeutics - Co and Capsida Will Each Have the Option to Co-develop and Co-commercialize the Program That the Other Company Leads.
Crispr Therapeutics - Following Option, Co, Capsida to Equally Share Research, Development & Commercialization Costs & Profits Worldwide Related to Product.
Crispr Therapeutics - Capsida Will Be Also Responsible for Process Development, Clinical Manufacture of Both Programs.
Further Company Coverage: Crsp.
Bn.
((reuters.
Briefs@thomsonreuters.
Com;)).